tiprankstipranks
Advertisement
Advertisement
Kymera Therapeutics initiated with a Buy at Canaccord
PremiumThe FlyKymera Therapeutics initiated with a Buy at Canaccord
1M ago
Kymera Therapeutics initiated with a Buy at Canaccord
Premium
The Fly
Kymera Therapeutics initiated with a Buy at Canaccord
1M ago
AMD upgraded, Reddit downgraded: Wall Street’s top analyst calls
Premium
The Fly
AMD upgraded, Reddit downgraded: Wall Street’s top analyst calls
1M ago
Kymera Therapeutics announces Gilead option exercise to license KT-200
PremiumThe FlyKymera Therapeutics announces Gilead option exercise to license KT-200
2M ago
Kymera Therapeutics presents results from BroADen Phase 1b AD trial of KT-621
Premium
The Fly
Kymera Therapeutics presents results from BroADen Phase 1b AD trial of KT-621
3M ago
Kymera Therapeutics Updates Bylaws on Federal Securities Litigation
Premium
Company Announcements
Kymera Therapeutics Updates Bylaws on Federal Securities Litigation
3M ago
Kymera Therapeutics price target raised to $120 from $110 at Citi
PremiumThe FlyKymera Therapeutics price target raised to $120 from $110 at Citi
4M ago
Kymera Therapeutics Signals Strong Momentum In Earnings Call
Premium
Company Announcements
Kymera Therapeutics Signals Strong Momentum In Earnings Call
4M ago
Kymera’s KT-579 Enters First-in-Human Testing: What Early Trial Progress Means for Investors
Premium
Company Announcements
Kymera’s KT-579 Enters First-in-Human Testing: What Early Trial Progress Means for Investors
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100